Enable Injections inks development deals for wearable drug-delivery device

Enable Injections said today that it inked development deals with Apellis Pharmaceuticals and UCB for its enFuse on-body drug-delivery device.

The Cincinnati-based company has ongoing partnerships with five companies. Enable Injection’s enFuse device is designed for the subcutaneous delivery of high-volume drugs, including monoclonal antibodies.

Get the full story at our sister site, Drug Delivery Business News.

The post Enable Injections inks development deals for wearable drug-delivery device appeared first on MassDevice.

from MassDevice https://ift.tt/2K0OiBY